Navigating Advances in NSCLC With EGFR PACC Mutations - Episode 1

EGFR PACC Mutations in NSCLC

November 10, 2025

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Alexander I. Spira, MD, PhD

Panelists discuss how classifying EGFR mutations into molecular subgroups, including PACC, refines diagnosis and informs targeted treatment decisions.

Now Viewing

EP. 1: EGFR PACC Mutations in NSCLC

EP. 2: EGFR PACC Mutation Identification Strategies in NSCLC

EP. 3: Current Treatment Approaches in NSCLC With PACC Mutations

EP. 4: Emerging Data on Firmonertinib for PACC Mutations in NSCLC

EP. 5: Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

EP. 6: Future Directions for NSCLC With PACC Mutations

Panelists discuss how understanding the classification of EGFR mutations—classical-like, T790M-like, P-loop and αC-helix compressing (PACC), and exon20—has reshaped diagnostic and therapeutic strategies in non–small cell lung cancer (NSCLC).They emphasize that PACC mutations represent a distinct molecular group with unique structural effects on the kinase domain, altering tyrosine kinase inhibitor binding and resistance mechanisms.

Panelists discuss how PACC mutations, though relatively uncommon, include variants like G719X, S768I, E709X, and V774M. They note the growing recognition of these alterations in molecular profiling, highlighting their nuanced impact on drug sensitivity and disease progression.

Panelists discuss how this classification framework enables more precise patient stratification, guiding therapy selection and the interpretation of emerging trial data. This approach is seen as a cornerstone for personalized oncology in NSCLC management.

We expand abbreviations in each segment summary because they stand alone once the video segment is clicked on and goes to the separate page.